Suzhou Ascentage Pharma has achieved a significant milestone with the conditional approval of Lisaftoclax Tablets (brand name: Lishengtuo, research code: APG-2575) by the National Medical Products Administration (NMPA). ✨ This approval is for the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in adult patients who have failed at least one prior … Continue reading Lisaftoclax Tablets: The First Domestic Bcl-2 Inhibitor Approved for CLL/SLL Treatment in China